Back to Search
Start Over
Supplementary Data from Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Data from Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....bb37fd055436b03a79e0aa934cdcb18e
- Full Text :
- https://doi.org/10.1158/1078-0432.22486952.v1